Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Date:2/24/2009

approximately 81 dilutive shares which did not change earnings per share. NEKTAR THERAPEUTICS CONSOLIDATED BALANCE SHEETS (In thousands) (unaudited) December 31, December 31, ASSETS 2008 2007 (1) Current assets: Cash and cash equivalents $155,584 $76,293 Short-term investments 223,410 406,060 Accounts receivable, net of allowance 11,161 21,637 Inventory 9,319 12,187 Other current assets 6,746 7,106 Total current assets 406,220 523,283 Property and equipment, net 73,578 114,420 Goodwill 76,501 78,431 Other assets 4,237 8,969 Total assets $560,536 $725,103 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $13,832 $3,589 Accrued compensation 11,570 14,680 Accrued clinical trial expenses 17,622 2,895 Accrued expenses to contract manufacturers - 40,444 Accrued expenses 9,923 9,551 Deferred revenue, current portion 10,010 19,620 Other current liabilities 5,417 7,313 Total current liabilities 68,374 98,092 Convertible subordinated notes 2
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
2. Nektar Announces Retirement of Irwin Lerner from Board of Directors
3. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Nektar Therapeutics to Webcast R&D Day on November 12th
6. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
10. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
11. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 ITRA Global, one of the ... commercial real estate, has further expanded its global reach ... and Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman ... ITRA Global / ACORPP (Australian Corporate Property and Projects) ... providing property services to a wide range of clients ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... Dec. 19, 2014  Roche (SIX: RO, ROG; OTCQX: ... Inc. (Bina), a privately held company based in ... Bina provides a big data platform for centralized ... data. Bina,s proprietary on-market Genomic Management Solution, Bina-GMS ... to perform fast and scalable analyses to maximize ...
(Date:12/19/2014)... , Dec. 19, 2014 Research and Markets ... addition of the "Technology Innovations in Smart ... http://photos.prnewswire.com/prnh/20130307/600769 ... Smart Fabrics" offers a detailed assessment on technological ... Key Findings: 1. The Smart ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Technology Innovations in Smart Fabrics (Technical Insights) 2
... Physical Laboratory (NPL) is working to provide more reliable measurement ... which could lead to much more accurate devices in the ... in 1986. It uses a nano-sized probe to feel the ... Braille on an extremely small scale. The technique can also ...
... SEATTLE, Oct. 20 Adaptive TCR Technologies, a ... the release of its immunoSEQ™ profiling service and ... provide researchers and clinicians the ability to profile ... level of detail that has never before been ...
... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin ... its proprietary drug-delivery platforms to develop treatments in areas ... has submitted additional patent applications, covering its Cobalamin-mediated oral ... drugs, as a result of the growing interest surrounding ...
Cached Biology Technology:Measuring the electrical properties of nano-crystals 2Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing. 2Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing. 3Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... skin. Cancer is not a static disease but during ... defences adapting to new environmental circumstances, protecting against chemotherapy ... Until now little was known about the mechanisms ... is a particularly intriguing way in which a tumour ...
... of carbon in the world,s oceans, which cover 70 ... climate cycles, with many questions remaining unanswered. Between 200 ... "twilight zone" where insufficient sunlight penetrates for microorganisms to ... resident at these depths capture carbon dioxide that they ...
... of spring-run Chinook salmon in California by the end ... at UC Davis, the Stockholm Environment Institute and the ... for managing water resources to protect the salmon runs, ... Thompson, director of the Center for Aquatic Biology and ...
Cached Biology News:Why cancer cells change their appearance? 2Up from the depths: How bacteria capture carbon in the 'twilight zone' 2Warming streams could be the end for salmon 2
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 9 ... tubes. Box dimensions: 13 x 13 x ...
RABBIT ANTI PARATHION...
RABBIT ANTI BACTERIAL HISTIDASE...
Biology Products: